First Berlin Equity Research updated its rating on aap Implantate AG, maintaining a 'Buy' and highlighting the company's MDR certification and 2026 EBITDA guidance. The company also plans a €2 million capital increase to fund strategic objectives, which could be dilutive but supports long-term growth.
First Berlin Equity Research issued an updated research note on aap Implantate AG, maintaining a 'Buy' rating and a target price of €1.68. This update highlights several positive developments, including the company's entire product portfolio being MDR-certified since Q1 2026, providing a competitive advantage. The company also plans a €2 million capital increase to support strategic objectives, which, while potentially dilutive in the short term, is crucial for funding growth initiatives. Management's 2026 EBITDA guidance of €-1 million to +1.5 million suggests the potential for operational break-even, a significant milestone after a decade. The progress on the antibacterial silver coating technology, with regulatory approval anticipated in 2028 or 2029, offers a long-term growth opportunity. Traders should consider the short-term dilution risk from the capital increase against the long-term potential of achieving profitability and new product approvals.